ｨｦ 07 ｨ ｨｮｨｨ02ｨｪ07ｨｰ ｨｦ ｨｪｨ ｨｦ ｨ ｨｪ00ｨｦ0804ｨｺ

Transcription

1 ORIGINAL PAPER 03ｨｬ0802ｨｦ0908ｨ 08ｨ 09ｨ ｨｺ ｨｨ04ｨｮ04ｨｰ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｮ0007 ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｮ01ｨｮ0004ｨｬｨ 00ｨｦｨｺ07 08ｨ 09ｨ ｨｺ ｨｨ04ｨｮ04, ｨ 08ｨｹ ｨｦ01ｨｦｨｺ0201ｨｬ06ｨｪ07 ｨｦｨ , ｨ - ｨｮｨｨ02ｨｪ06ｨｪ ｨｪ00ｨ ｨｦ ｨｮ02 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ ｨｪｨ ｨｦ 01ｨｦ02ｨｨｨｪ06ｨｰ ｨ ｨｺ ｨｮｨｺ0708ｨｹ ｨｪｨ 01ｨｦ ｨｪ07ｨｮ0701ｨｬ ｨｪ ｨ ｨｮｨｬｨ 00ｨｦｨｺｨｹ000400ｨ ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｴｨｰ ｨｰ ｨｰ (INR), ｨｺｨ ｨｦ 00ｨｦｨｰ 0208ｨｦ080507ｨｺ06ｨｰ, ｨｬ ｨｨ04ｨｺｨ ｨｪ 07ｨｦ 08ｨ 09ｨ ｨｺ ｨｨ0705ｨｬ02ｨｪ07ｨｦ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ｨｮ0007 ｨｦｨ ｨｪ ｨｬｨ ｨｰ ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 0509 ﾂｨｦｨｮ ｨｦ ｨ ｨｬ02 30 ｨ ｨｮｨｨ02ｨｪ0208ｨｰ, ｨｮ07ｨｬ0209ｨ ｨ 09ｨ ｨｺ ｨｨ0705ｨｬ ｨｮ05ｨｪ ｨ 09ｨ ｨｺ ｨｨ0705ｨｬ02ｨｪｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨ ｨｪ ｨｦ000802ｨｰ 0202ｨ 09ｨｬ070007ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ: ｨｮｨｨ0200ｨｦｨｺ06ｨｰ 09ｨ ｨｰ 371, ｨｺ070508ｨｦｨｺ07 ｨｬｨ 09ｨｬｨ , 09ｨ 0509ｨｦ ｨｨ02ｨｦ02ｨｰ 24, ｨｨ0907ｨｬ0906ｨｮ02ｨｦｨｰ 59, ｨｺ ｨｪ07ｨｬｨｦｨｺ07 ｨｨ0907ｨｬ090702ｨｦ0508ｨ 11, ｨｺ , ｨｺ0107ｨｮ02ｨｦｨｰ ｨ 09ｨ ｨｺ ｨｨ04ｨｮ04 ｨ 08ｨｹ 0007 ｨｦｨ ｨｦ05ｨ ｨｬ0905ｨｪ02ｨｦ ｨｬ ｨｰ ｨｦｨｮ000709ｨｦｨｺ0705, ｨｺｨ ｨｨ0709ｨｦｨｮｨｬｨｹ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨ ｨｮ000409ｨｦｨ ｨｺｨｹ ﾂ07 ｨｬ02 2 ｨ ｨｪ00ｨｦ0109ｨ ｨｮ000709ｨｦｨ ｨｨ0907ｨｬ ｨ ｨｮ0008ｨｪ04ｨｰ (ISI: 1,0ｨC1,03) ｨｺｨ ｨｦ ｨ ｨｺ ｨｨｨｴｨｰ 0905ｨｨｨｬｨｦｨｮ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｰ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ﾂ ｨ ｨｦ 02ｨｦ01ｨｦｨｺ07 ｨｺ050900ｨ 08ｨ 09ｨ ｨｺ ｨｨ04ｨｮ04ｨｰ ｨｺｨ ｨｦ 09ｨｦ ｨｦ06ｨｪ 00ｨｦｨ ｨｰ 08ｨ ｨｪ0002ｨｰ ｨｪ 0004ｨｪ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ0007 ｨｹ08ｨｴｨｰ 04 01ｨｦｨ , 00ｨ ｨｬｨ ｨｺｨ, 07ｨｦ ﾂ02ｨｦ ｨｦｨｺ06ｨｰ ｨｺｨ ｨｦ ｨｪ00ｨｦｨ 0009ｨｦｨｺ06ｨｰ ｨｬ0905ｨｮ02ｨｦｨｰ, 04 ｨｺ0504ｨｮ ｨｰ-ｨｮ00ｨｹ ﾂ07ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ(INR) 0700ｨ ｨｪ 2,5ｨC3,5 00ｨｦｨ ｨｮｨｨ0200ｨｦｨｺ06ｨｰ 09ｨ ｨｰ, ｨ ｨｦｨ ｨｺ05 ｨｬ07ｨｮ ﾂ0205ｨｬｨ 00ｨ, ｨｪ0201ｨｬ07ｨｪｨｦｨｺ07ｨｰ 02ｨｬ ｨｰ, ｨｦｨｺ07ｨｰ ｨｨ09ｨｹｨｬ09ｨｴｨｮ04ｨｰ, 2,0ｨC3,0 00ｨｦｨ ｨｺ070508ｨｦｨｺ07 ｨｬｨ 09ｨｬｨ , 02ｨｪ 00ｨｴ 0905ｨｨ02ｨｦ ｨｦｨｺ07 ｨｨ09ｨｹｨｬ09ｨｴｨｮ04, 08ｨｪ0201ｨｬ07ｨｪｨｦｨｺ07 02ｨｬ , 06ｨｬ0209ｨ 00ｨｬｨ ｨｺｨ ｨｦ 2,0ｨC2,5 00ｨｦｨ 0809ｨｹ ｨｰ 02ｨｪ 00ｨｴ 0905ｨｨ02ｨｦ ｨｦｨｺ07ｨｰ ｨｨ09ｨｹｨｬ09ｨｴｨｮ04ｨｰ. 08ｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ ﾂ0904ｨｮｨｦｨｬ070807ｨｦ07ｨｨ04ｨｺｨ ｨｪ 0700ｨ ｨｪ ｨ ｨｮ02ｨｪ07ｨｺ0701ｨｬｨ 09ｨｹ0504 (90%) ｨｺｨ ｨｦ 09ｨ 0902ｨ 0908ｨｪ04 (10%), ｨｬ02 07 ﾂｨｴ0908ｨｰ ｨｮ01ｨｪ0101ｨ ｨｮｨｬｨｹ ｨ ｨｮ08ｨｦ0908ｨｪ04ｨｰ ｨｺｨ ｨｦ ｨｮ02 02ｨｦ01ｨｦｨｺ06ｨｰ ｨｦ080006ｨｮ02ｨｦｨｰ 0408ｨ 0908ｨｪ04 ｨｬｨｦｨｺ ｨｬ0709ｨｦｨ ｨｺ ｨｰ ｨｬ06ｨｮ04 ｨｮ01 ﾂｨｪｨｹ000400ｨ ｨ ｨｮ000409ｨｦｨ ｨｺ ﾂ0701 ｨｺｨ ｨｦ 0004ｨｰ 0905ｨｨｨｬｨｦｨｮ04ｨｰ 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｦ03ｨｹｨｬ02ｨｪ04 ｨｮ ｨｰ 0700ｨ ｨｪ ｨ - ｨｪ ｨｬ050102ｨｰ, ｨｬ02 01ｨｦｨ ｨｺ01ｨｬ05ｨｪｨｮ02ｨｦｨｰ ｨ 08ｨｹ 1ｨC ｨｬ050102ｨｰ. 03 ｨｨ0209ｨ ｨｦｨｺｨｹｨｰ ｨｮ00ｨｹ ﾂ07ｨｰ 0700ｨ ｨｪ 0208ｨｦ0001 ﾂ07ｨｰ ｨｮ ｨC71%, 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｰ 1998 ｨ ｨｪｨ ﾂｨｨ04ｨｺｨ ｨｪ 8 ｨｨ0907ｨｬ0906ｨｮ02ｨｦｨｰ ｨｬ02 INR ｨｬｨｦｨｺ09ｨｹ ｨｨ0209ｨ ｨｦｨｺ ｨｰ, 14 ｨ ｨｦｨｬ070909ｨ ｨｰ ｨｬ02 INR ｨｬ0200ｨ ｨｺｨ ｨｦ 2 ｨｬ02 ｨｮ01ｨｪ0101ｨ ｨｮｨｬｨｹ ｨ ｨｮ08ｨｦ0908ｨｪ04ｨｰ. 08ｨ ｨ ｨｮｨｬｨ 0005 ｨｬｨ ｨｰ, ｨｮ0100ｨｺ09ｨｦｨｪｨｹｨｬ02ｨｪｨ ｨｬ02 00ｨ 01ｨｦ02ｨｨｨｪ ｨｬ06ｨｪｨ, 0208ｨｪｨ ｨｦ ｨｦｨｺｨ ｨｪ070807ｨｦ0400ｨｦｨｺ TA ｨｦ0001 ﾂ08ｨ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 0206ｨ ｨ ｨｦ ｨ 08ｨｹ 0004 ｨｮ01ｨｪ060802ｨｦｨ ｨ ｨｮｨｨ02ｨｪ0705ｨｰ ｨｺｨ ｨｦ 0004 ｨｮ0002ｨｪ07 ｨｮ01ｨｪ020900ｨ ｨｮ08ｨ ｨｬ ｨｪ ｨｨ01ｨｪ ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｬ02 ｨｮｨｺ0708ｨｹ 0004 ｨｬ0208ｨｴｨｮ04 00ｨｴｨｪ ｨｨ0907ｨｬ0906ｨｮ02ｨｴｨｪ ｨｺｨ ｨｦ 00ｨｴｨｪ ｨ ｨｦｨｬ070909ｨ 00ｨｦ06ｨｪ. 0405ｨ ｨ ｨｦ ﾂ05ｨｪ07ｨｪ00ｨ ｨｦ ｨｮ ｨ ｨｪｨｴｨｬ06ｨｪｨ ｨｦｨ ｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｪｨ ｨｦ ｨ ｨｪ0500ｨｺ04 ｨｪｨ 0104ｨｬｨｦ ｨｨ0705ｨｪ ｨｺｨ ｨｦ ｨｪｨ ｨｺｨ 00ｨ ｨｪ02ｨｬ04ｨｨ0705ｨｪ ｨ ｨｪ ﾂ0609ｨ ﾁ , 17(0701ｨｬ ｨｴｨｬｨ 00ｨｦｨｺｨｹ ﾂ07ｨｰ 09):110ｨC114 ARCHIVES O1 7 HELLENIC MEDICINE 2000, 17(Supplement A):110ｨC114 K. 00ｨ 09ｨ 00ｨｺｨｹｨｰ, M ｨｦｨ, E. 02ｨｦ0002ｨｪ , B. 08ｨｮ ｨｪ04ｨｰ, ｨｮｨｦ050104ｨｰ, ｨｹｨｪ0003ｨ, , ｨｬｨｦｨｺ0705, ｨ 00ｨｦｨ ｨｪ , ｨｴ0900ｨｹ ｨｰ, ｨｮ ｨｺ0701, ｨｪ ｨ 1o ｨｦ ｨｦｨ ｨｺｨｹ 0806ｨｪ ｨｦｨｬ070107ｨｮ08ｨ ｨｰ ｨｺ ｨｦ ｨｦ ｨｦｨ ｨｺｨｹ 0102ｨｪｨｦｨｺｨｹ 0107ｨｮ07ｨｺ07ｨｬ ｨｨ04ｨｪ06ｨｪ Experience of monitoring patients in anticoagulant therapy ｨｦｨｰ ｨｪ00ｨｦ010905ｨｮ02ｨｦｨｰ 09ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺｨｹ ｨｦｨ bstract at the end of the article 08ｨ ｨ 08ｨ ﾂ09ｨｹｨｪｨｦｨ, ｨｬ ｨｺｨ 0505 ｨｮ ﾂ0201ｨｦｨ ｨｮｨｬ06ｨｪ02ｨｰ ｨｬ ｨｰ ｨｺｨ ｨｨ070908ｨｮ0004ｨｺ ｨｦｨｮ ｨｪ00ｨ ｨｮ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ - 00ｨｴ0007ｨｰ, ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｪ00ｨ ｨｦ ｨｮ ｯ ｨ ｨｪ ｨｦｨ ｨｮ0100ｨｺ02ｨｺ09ｨｦｨｬ06ｨｪ07 ﾂ0907ｨｪｨｦｨｺｨｹ 01ｨｦ05ｨｮ0004ｨｬｨ ｯ ｨｹ ｨｴ07ｨｰ ｨｦｨ ｨｮ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｮ00ｨ 0208ｨｦｨｨ01ｨｬ ｨ 0208ｨｪｨ ｨｦ ｨ ｨｮｨｬｨ ｨｪ 08ｨ 09ｨ 00ｨｹｨｪ00ｨｴｨｪ ｨｹ08ｨｴｨｰ ｨ 0100ｨｹ ﾂ0907ｨｪｨ ｨｴｨｪ 02ｨ 09ｨｬ05ｨｺｨｴｨｪ ｨ 08ｨｹ 0007ｨｪ ｨ - ｨｮｨｨ02ｨｪ07, 07ｨｦ 01ｨｦｨ ｨｦ000400ｨｦｨｺ06ｨｰ ｨｮ01ｨｪ07ｨｨ02ｨｦ02ｨｰ, ｨ ｨｺ010908ｨｴｨｰ 04 ｨ 06ｨｦ0708ｨｦｨｮ0008ｨ ｨ ｨｮ000409ｨｦｨ ｨｺ ﾂ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ - 00ｨｴ0007ｨｰ Wright, 07 ｨ ｨｬ0209ｨｦｨｺｨ ｨｪｨｹｨｰ 0809ｨｴ000708ｨｹ0907ｨｰ ｨｮ0004ｨｪ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ0007 ｨ 08ｨｹ 0007 ｨｮ00ｨｹｨｬｨ, ｨｮ01ｨｬ080609ｨ ｨｪ02 00ｨｦｨ ｨｬ0209ｨ 00ｨｬｨ ｨｬ0107ｨｺｨ : 0102ｨｪ ｨ 09ｨｺ0208 ｨｪｨ 0007ｨｪｨｦｨｮ ｨｹ-

2 ｨｦ 07 ｨ ｨｮｨｨ02ｨｪ07ｨｰ ｨｦ ｨｪｨ ｨｦ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ ｨｦ 02-09ｨｴ0007ｨｮ02ｨｦｨｰ ｨｦ ｨｪｨ ｨ 08ｨ ｨｪ0004ｨｨ0705ｨｪ 0208ｨｪｨ ｨｦ: 08ｨｹｨｮ ｨｹｨｮ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ ｨ 09ｨｬ05ｨｺ0701, 00ｨｦｨ 08ｨｹｨｮ04 01ｨｦ0509ｨｺ02ｨｦｨ, 0807ｨｦｨｹ ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｺｨ ｨｦ 08ｨｹｨｮ07 ｨｮ00ｨ ｨｨ0209ｨｹ 0208ｨｪｨ ｨｦ ｨｰ ｨ 0100ｨｹ ｨｺｨ ｨｦ0509ｨｺ02ｨｦｨ 0004ｨｰ ｨｨ0209ｨ ｨ ｨｰ. 0908ｨｹ ｨｰ ｨｺ05ｨｦｨｪｨｦｨｺ06ｨｰ ｨｬ ｨｰ 0208ｨｪｨ ｨｦ ｨｪ 00ｨｪｨｴｨｮ00ｨｹ ｨｹ00ｨｦ, 04 ｨ 08ｨｹ ｨｮ00ｨｹｨｬｨ 0007ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ ｨｪｨ ｨｦ ｨ ｨｮ02ｨ 0507ｨｰ ｨｺｨ ｨｦ ｨｦｨｮｨｮｨｹ ｨ ｨｮｨｬｨ 00ｨｦｨｺ07 ｨ ｨｪ 07 ｨ ｨｮｨｨ02ｨｪ07ｨｰ ｨｮｨｺ0200ｨ ｨｦ 02ｨｪ00ｨｹｨｰ 00ｨｴｨｪ ｨｺｨ ｨｨ0709ｨｦｨｮｨｬ06ｨｪｨｴｨｪ 00ｨｦ ｯ ｨ 0100ｨｹｨｪ ｨｨ0209ｨ ｨｦｨｺ06ｨｪ ｨｴｨｪ 00ｨｦｨ ｨｦｨｮｨｮｨｹ ｨ 08ｨｹ % ﾂ09ｨｹｨｪ0701 ｨｨ0209ｨ ｨ ｨｰ ｨ ｨｮｨ ｨｪ ｨ 08ｨｹ 00ｨｹ0002 ｨ 09ｨｺ020006ｨｰ 0102ｨｺｨ ｨｰ 00ｨｦｨ ｨｪｨ 02ｨｨ05ｨｮ0701ｨｬ02 ｨｮ ｨ ｯ80, ﾂｨｦｨｮｨ ｨｪ ｨｪｨ ｨｮ ｨｪ00ｨ ｨｦ ｨｬ ｨｮｨ ｨｬ ｨ ｨｬｨ 00ｨ 0004ｨｰ 0807ｨｦｨｹ000400ｨ ｨｰ ﾂ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｦ0001 ﾂ08ｨ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 02-06ｨ ｨ ｨｦ ｨ 08ｨｹ 0004 ﾂ ｨｮ ｨｺｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ ｨ 09ｨｬ05ｨｺ0701 ｨｮ02 01ｨｹｨｮ ｨｦｨ ｨｪｨ ｨｬ04ｨｪ ｨｺｨ ｨｮ0709ｨ 0906ｨｰ ｨｺｨ ｨｦ 0208ｨｦｨｺ08ｨｪ0101ｨｪ02ｨｰ ｨ ｨｦｨｬ070909ｨ ｨｰ, 02ｨｪ06 ｨｮ0100 ﾂ09ｨｹｨｪｨｴｨｰ 0102ｨｪ 02-08ｨｦ ｨｦ ｨｬｨｦ ｨ ｨｨ09ｨｹｨｬ09ｨｴｨｪ ｨｪ ｨｺ00ｨ ｨｮ04 00ｨｴｨｪ ｨｮ ﾂ04ｨｬｨ 00ｨｦｨｮｨｬ06ｨｪｨｴｨｪ ｨｺｨ ｨｦ ｨ 08ｨｹ 0004ｨｪ ｨｺｨ ｨｨ0709ｨｦｨｮｨｬ06ｨｪ04 00ｨｦｨ ｨｺ05ｨｨ02 ｨｺ05ｨｦｨｪｨｦｨｺ ｨｴｨｮ04 01ｨｦ0509ｨｺ02ｨｦｨ ｨｺｨ ｨｦ ｨｰ ｨｨ0209ｨ ｨ ｨｰ. 01ｨｦｨ ｨｹ0007 ｨ 0100ｨｹ, 0208ｨｪｨ ｨｦ ｨ ｨｪｨ 00ｨｺｨ ｨ ｨｮ000409ｨｦｨ ｨｺｨｹｨｰ ﾂ07ｨｰ ｨｺｨ ｨｦ ｨｨｨｬｨｦｨｮ04 ｨｪｨ 0008ｨｪ0200ｨ ｨｦ ｨｺｨ ｨｦ ｨｮ0004 ﾂ0609ｨ ｨｬｨ ｨｰ ｨｮ ｨ ｨｪｨｴｨｬ06ｨｪｨ ｨｦｨ ｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｹ08ｨｴｨｰ 0008ｨｪ0200ｨ ｨｦ ｨｮ0004ｨｪ ｨｺｨ ｨｦ 01ｨｦ02ｨｨｨｪ06ｨｰ ｨｨ01ｨｪ07ｨｰ 00ｨｦｨ 0009ｨｹｨｰ 00ｨｴｨｪ ｨｦｨ ｨｴｨｪ ｨ - ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｦ ｨｪｨ ｨｬ : ｨC ｨｪｨ 01ｨｦｨ 00ｨｪ06ｨｮ02ｨｦ ｨｺｨ ｨｦ ｨｪｨ ｨ ｨｪ00ｨｦｨｬ0200ｨｴ0808ｨｮ02ｨｦ 0600ｨｺｨ ｨｦ09ｨ ｨｺ05ｨｨ ｨｦ080507ｨｺ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨC ｨｪｨ ﾂ02ｨｦ 0004 ｨｬ02ｨｨ ｨ, 00ｨ ﾂ0904ｨｮｨｦｨｬ070807ｨｦ0705ｨｬ02ｨｪｨ 00ｨｦｨ ｨｺ05ｨｨ02 ｨｬ06ｨｨ ｨ ｨｪ00ｨｦ0109ｨ ｨｮ000709ｨｦｨ ｨｺｨ ｨｦ ｨｦ ｨ 00ｨｴｨｪ ｨ 0100ｨｹｨｬｨ 00ｨｴｨｪ ｨｬ04 ﾂｨ ｨｪ04ｨｬ0500ｨｴｨｪ ｨｰ, ｨC ｨｪｨ ｨｺｨ ｨｦ ｨｪｨ 02ｨｺ08ｨ ｨｦ ｨｦ ｨｮ01ｨｪ02 ﾂ06ｨｰ ｨｰ ｨ - ｨｮｨｨ02ｨｪ0208ｨｰ ｨｪ00ｨ ｨｦ ｨｮ02 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ0007. E08ｨｪｨ ｨｦ ｨｮｨ 0206ｨｰ ｨｹ00ｨｦ 04 ｨｮ01ｨｪ020900ｨ ｨｮ08ｨ ｨ ｨｮｨｨ02ｨｪ07-00ｨｦｨ ｨｪｨ ｨｦ 07 ｨ ｨｺ090700ｨｴｨｪｨｦｨ 0807ｨｰ 0508ｨｨ07ｨｰ 0004ｨｰ 0208ｨｦ0001 ﾂ08ｨ ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ - 00ｨｴ0007ｨｰ, ｨｰ ｨｹ ｨｰ 00ｨｴｨｪ ﾂｨｦ05ｨｦ0501ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｪ00ｨ ｨｦ ｨｹ0507 ｨｺｨ ｨｦ ｨｦｨｮｨｮｨｹ ｨｮ02 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ ｨ ｨ 08ｨ ﾂ09ｨｹｨｪｨｦｨ ｨｮ01ｨｪ02 ﾂ06ｨｰ ｨ 0106ｨ ｨｪ07ｨｬ06ｨｪ04 01ｨｦ02ｨｨｨｪ06ｨｰ 0202ｨ 09ｨｬ ｨｺ07ｨｦｨｪ06ｨｪ 0809ｨｴ0007ｨｺｨｹ0505ｨｴｨｪ ｨｬ ｨ 09ｨｬ ｨｪｨｦｨ 08ｨ ｨｰ ｨｬ02ｨｨ ｨ ｨｰ, 02ｨｪｨｦｨ ｨｹ ｨｺ0209ｨ ｨｮ04ｨｰ 00ｨｴｨｪ ｨ ｨｮ000409ｨｦｨ ｨｺ06ｨｪ ｨ ｨｮｨｬ0500ｨｴｨｪ ｨｺｨ ｨｦ 02ｨｪｨｦｨ 08ｨｴｨｪ ｨｦ06ｨｪ ｨｹｨｮ07ｨｪ ｨ ｨｮ00ｨｹ ﾂ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 0208ｨｦ ｨｪ ｨｬｨｦ ｨ ｨｦ01ｨｦｨｺ0201ｨｬ06ｨｪｨｴｨｪ ｨｦｨ ｨｴｨｪ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｺｨ ｨｦ 0206ｨ 00ｨｴ0007ｨｰ ｨ 08ｨｹ ｨ ｨｮ01ｨｬ080209ｨ ｨｮｨｬ0500ｨｴｨｪ ｨｮ02 02ｨｨｨｪｨｦｨｺｨｹ ｨｮｨｺ0708ｨｹ ｨｪｨ 01ｨｦ ｨｪ07ｨｮ0701ｨｬ ｨｪ ｨ ｨｮｨｬｨ 00ｨｦｨｺｨｹ000400ｨ ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｴｨｰ ｨｰ ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ (INR) ｨｺｨ ｨｦ 00ｨｦｨｰ 0208ｨｦ080507ｨｺ06ｨｰ ｨ - 08ｨｹ 00ｨｦｨｰ ｨｬ0200ｨ ｨｰ ｨｨ0209ｨ ｨｦｨｺ ｨｰ, ｨｬ ｨｨ04ｨｺｨ ｨｪ 07ｨｦ 08ｨ 09ｨ ｨｺ ｨｨ0705ｨｬ02ｨｪ07ｨｦ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ｨｮ0007 ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｪ ｨｦｨｬ070107ｨｮ08ｨ ｨｰ ｨｺｨ ｨｦ 09ｨｦｨｬ ｨｦ05ｨｦｨｺ06ｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｮ07ｨｺ07ｨｬ ｨｬｨ ｨｰ 00ｨｦｨ ｨｰ ｨｦｨ ﾂｨｦｨｮ ｨｦ ｨ ｨｬ02 30 ｨｬｨｹｨｪ07 ｨ - ｨｮｨｨ02ｨｪ0208ｨｰ, 02ｨｪ06 ｨｮ07ｨｬ0209ｨ 08ｨ 09ｨ ｨｺ ｨｨ0705ｨｪ00ｨ ｨｦ ｨｮ02 ｨ 0100ｨｹ 850 ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ｨｦｨ ｨｺ05ｨｬｨ ｨｪｨｮ04 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨ ｨｪ ｨｰ 02ｨ 08ｨｪ0200ｨ ｨｦ ｨｮ0004ｨｪ 02ｨｦｨｺｨｹｨｪｨ ｨｪ ｨ 09ｨ ｨｺ ｨｨ0705ｨｬ02ｨｪｨｴｨｪ ｨｰ 1998 ｨ ｨｮｨｨ02ｨｪ06ｨｪ 578, ｨｬ06ｨｮ04ｨｰ 0405ｨｦｨｺ08ｨ ｨｰ: 47 ﾀ11, , ｨｪ010902ｨｰ (56,66%), ｨｪｨ 08ｨｺ02ｨｰ (43,34%) ｨ ｨｰ, 0208 ﾂｨ ｨｪ ｨｴｨｰ ｨ ｨｦ0008ｨ 0202ｨ 09ｨｬ070007ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｮｨｨ0200ｨｦｨｺ06ｨｰ ｨｬ0200ｨ 0505ｨｦｨｺ06ｨｰ 09ｨ ｨｰ ｨｺｨ 0901ｨｦ05ｨｰ (ｨ ｨｰ, ｨｬｨｦ ｨｦ010705ｨｰ 07 ｨｬｨｦｨｺ0006ｨｰ) 371 (64%), ｨｺ070508ｨｦｨｺ07 ｨｬｨ 09ｨｬｨ (16,08%), 09ｨ 0509ｨｦ ｨｨ02ｨｦ02ｨｰ (ｨ ｨｪ ｨｺ02ｨｦｨ 07 ｨｮ0006ｨｪｨｴｨｮ04 ｨｺｨ 0901ｨｦｨ ｨｺ06ｨｪ 09ｨ ｨｴｨｪ) 24 (4,15%), ｨｨ0907ｨｬ0906ｨｮ02ｨｦｨｰ 59 (10,2%), ｨｺ ｨｪ07ｨｬｨｦｨｺ07 ｨｨ0907ｨｬ090702ｨｦ0508ｨ 11 (1,9%), ｨｺ ｨｨ0907ｨｬ090702ｨｦ0508ｨ 15 (2,59%), ｨｺ0107ｨｮ02ｨｦｨｰ 5 (0,86%). 03ｨｦ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ 08ｨ 09ｨ 0806ｨｬ02ｨｨ04ｨｺｨ ｨｪ ｨｮ0007 ｨｦｨ ｨ 08ｨｹ 00ｨｦｨｰ ｨｺ05ｨｦｨｪｨｦｨｺ06ｨｰ ｨｮ07ｨｺ07ｨｬ ｨｬｨ ｨｰ ｨ ｨｺｨ ｨｦ ｨ 08ｨｹ ｨ ｨｪ07ｨｮ07ｨｺ07ｨｬ0208ｨ 0004ｨｰ ﾂ0609ｨ ｨｰ, ｨｦ01ｨｦｨ ｨ 0004ｨｰ 02-08ｨ 09 ﾂ08ｨ ｨｰ ｨｦ ﾂ02 ｨｺｨ ｨｺ ｨｨｨｬｨｦｨｮ04 07 ｨ ｨｨｨｬｨｦｨｮ ｨｰ ｨ - ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨｰ ｨ 00ｨｴ0007ｨｰ ｨ 09ｨ ｨｺ ｨｨ04ｨｮ ｨｦ05ｨ ｨｬ0905ｨｪ02ｨｦ ｨｬ ｨｰ ｨｦｨ 0009ｨｦｨｺ0705 ｨｦｨｮ000709ｨｦｨｺ0705, 0008ｨｪ0200ｨ ｨｦ ｨｺｨ ｨｨ0709ｨｦｨｮｨｬｨｹｨｰ ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, 0004ｨｰ 01ｨｦ0509ｨｺ02ｨｦｨ ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ (ｨｮ0100ｨｺ02ｨｺ09ｨｦｨｬ06ｨｪ07 ﾂ0907ｨｪｨｦｨｺｨｹ 01ｨｦ05ｨｮ0004ｨｬｨ ｯ ｨｹ ｨｴ- 03ｨｦｨｺｨｹｨｪｨ 1. 02ｨｦｨ ｨｺ05ｨｬｨ ｨｪｨｮ04 ｨ 09ｨｦｨｨｨｬ0705 ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, 00ｨ ｨC1999.

3 ｨｺｨ ｨｦ ｨｮ01ｨｪ 07ｨｰ ｨ ｨｪ ｨ ｨｬ ｨｪ 0805ｨｨ04ｨｮ04), ｨ ｨｮ000409ｨｦｨ ｨｺｨｹ ﾂ07 ﾂ09ｨｹｨｪ ｨｨ0907ｨｬ0908ｨｪ04ｨｰ ｨｬ02 ｨ 0100ｨｹｨｬｨ 00ｨ ｨｬ04 ﾂｨ ｨｪ07ｨｬｨ 00ｨ ｨｰ ｨｮ02 06ｨｺ0209ｨ ｨｮ04 INR (International Normalized Ratio=01ｨｦ02ｨｨｨｪ07ｨｰ ｨｺ0004ｨｰ 07ｨｬｨ ｨｮ04ｨｰ), ｨｬ ｨ ｨｪ00ｨｦ0109ｨ ｨｮ000709ｨｦｨ ｨｨ0907ｨｬ ｨ ｨｮ0008ｨｪ04ｨｰ (ISI: 1,0ｨC 1,03) (International Sensitivity Index=01ｨｦ02ｨｨｨｪ07ｨｰ ｨｺ0004ｨｰ 0201ｨ ｨｦｨｮｨｨ04ｨｮ08ｨ ｨｰ) 1,5 ｨｺｨ ｨｦ ｨ ｨｺ ｨｨｨｴｨｰ 0905ｨｨｨｬｨｦｨｮ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨ ｨｪ05 ｨｬ0609ｨ ｨｦ 07ｨｦ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ 02ｨｪ04ｨｬ020906ｨｪ07ｨｪ00ｨ ｨｪ ｨｺｨ ｨｪ 06ｨｪｨ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 00ｨｦｨ 00ｨｦｨｰ 08ｨｦｨｨｨ ｨｪ06ｨｰ 08ｨ 0902ｨｪ ｨｦ02ｨｰ 0004ｨｰ ｨ 00ｨｴ0007ｨｰ, 00ｨｦｨ ｨｦｨ ｨｰ, ｨｴｨｪ 02ｨ 09ｨｬ05ｨｺｨｴｨｪ ｨｺｨ ｨｦ 0004ｨｪ 0208ｨｦｨｺ07ｨｦｨｪｨｴｨｪ08ｨ ｨｬ ｨｦｨ ｨｮ02 24ｨｴ ｨｮ04 00ｨｦｨ ｨｺ05ｨｨ ｨｹ090504ｨｬ ｨｰ ｨｰ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ﾂ ｨｦ01ｨｦｨｺ07 ｨｺ050900ｨ 08ｨ 09ｨ ｨｺ ｨｨ04ｨｮ04ｨｰ ｨ ｨｪｨ ｨｪ00ｨ ｨｪ 00ｨ ｨ 0007ｨｬｨｦｨｺ ｨｰ ｨｮ0007ｨｦ ﾂ0208ｨ, 01ｨｦ0205ｨｨ01ｨｪｨｮ04, ｨｴｨｪ07, ｨｨ04ｨｮ04 00ｨｦｨ 0004ｨｪ ｨ ｨｪ00ｨ ｨｦ ｨｮ02 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ0007, 0007 ｨｨ0209ｨ ｨｦｨｺｨｹ ｨｰ 0004ｨｰ ｨ 00ｨｴ0007ｨｰ, 0007 ｨｦｨ ｨｰ 08ｨ 09ｨ ｨｺ ｨｨ0208, 0007 ｨ ｨｮｨｬｨ 0004ｨｰ ｨ ｨｮ04ｨｰ 02ｨｺ0209ｨ ｨｮｨｬ06ｨｪ07 ｨｮ02 INR, 04 ｨｮ01ｨｪｨｦｨｮ0006ｨｬ02ｨｪ ｨｮ ｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ ｨ 09ｨｬ05ｨｺ0701, ｨｹｨｬ02ｨｪ04 04ｨｬ020907ｨｬ04ｨｪ08ｨ ｨ ｨｮ04ｨｰ. 05 ｨｺ050900ｨ ｨ ｨｨ0705ｨｮ ｨｪ ｨ ｨｮｨｨ02ｨｪ07 ｨ ｨｺｨ ｨｦ ｨｰ ｨｦｨ ｨｰ, ｨｮ0004ｨｪ ｨｺｨ ｨ ｨｪ00ｨｦｨｬ ｨｦｨｮ , ｨｮ ｨｴｨｮ ｨｮｨｺ020304ｨｰ 07 02ｨｦｨｮｨ 00ｨｴ0007ｨｰ ｨｮ ｨｦ ｨｪ07ｨｮ07ｨｺ07ｨｬ ｨｹ050701ｨｰ ｨｰ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ﾂ ｨｨ04ｨｺ02 ｨ ｨｮ000201ｨｬ06ｨｪ07 09ｨｦ ｨｦ06ｨｪ 00ｨｦｨ ｨｰ 08ｨ ｨｪ0002ｨｰ ｨｪ 0004ｨｪ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ0007 ｨｹ08ｨｴｨｰ 04 ｨ ｨｮ04 ｨｨ0209ｨｬ07ｨｺ09ｨ ｨｮ08ｨ ｨｰ (ｨｺｨ 05ｨｮｨｴｨｪｨ ｨｰ, ｨｺ090507), 04 01ｨｦｨ (05ｨ ﾂｨ ｨｪｨｦｨｺ05 ｨｺｨ ｨｦ ｨ ｨｬ02 ｨｬ ｨｦ02ｨｺ00ｨｦｨｺｨｹ000400ｨ ｨｮ02 09ｨｦ00ｨ ｨｬ08ｨｪ04 08, ｨ ｨｪ00ｨ 00ｨｴｨｪ ｨ ｨｦ 0007 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺｨｹ), 00ｨ ｨｮ0100 ﾂ09ｨｹｨｪｨｴｨｰ 05ｨ ｨｬ09ｨ ｨｪｨｹｨｬ02ｨｪｨ 08ｨ ｨｦｨｺ05 07 ｨｬｨｹｨｪｨｦｨｬｨ ｨｬｨ ｨｺｨ, 07ｨｦ ｨｬｨｦｨｺ0906ｨｰ 07 ｨｬ ｨｰ ﾂ02ｨｦ ｨｦｨｺ06ｨｰ ｨｺｨ ｨｦ ｨｪ00ｨｦｨ 0009ｨｦｨｺ06ｨｰ ｨｬ0905ｨｮ02ｨｦｨｰ, 04 ｨｺ0504ｨｮ ｨｰ-ｨｮ00ｨｹ ﾂ07ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ (INR) 00ｨｦｨ ｨｰ 08ｨ 09ｨ ｨｺ ｨｨ0705ｨｬ02ｨｪ0701ｨｰ ｨ - ｨｮｨｨ02ｨｪ0208ｨｰ 0700ｨ ｨｪ: ｨ. INR=2,5ｨC3,5 00ｨｦｨ ｨｮｨｨ0200ｨｦｨｺ06ｨｰ 09ｨ ｨｰ, ｨ ｨｦｨ ｨｺ05 ｨｬ07ｨｮ ﾂ0205ｨｬｨ 00ｨ, ｨｪ0201ｨｬ07ｨｪｨｦｨｺ07ｨｰ 02ｨｬ ｨｰ, ｨｦｨｺ07ｨｰ ｨｨ09ｨｹｨｬ09ｨｴｨｮ04ｨｰ, 09. INR=2,0ｨC3,0 00ｨｦｨ ｨｺ070508ｨｦｨｺ07 ｨｬｨ 09ｨｬｨ , 02ｨｪ 00ｨｴ 0905ｨｨ02ｨｦ ｨｦｨｺ07 ｨｨ09ｨｹｨｬ09ｨｴｨｮ04, 08ｨｪ0201ｨｬ07ｨｪｨｦｨｺ07 02ｨｬ , 06ｨｬ0209ｨ 00ｨｬｨ, 00. INR=2,0ｨC2,5 00ｨｦｨ 0809ｨｹ ｨｪ 00ｨｴ 0905ｨｨ02ｨｦ ｨｦｨｺ07ｨｰ ｨｨ09ｨｹｨｬ09ｨｴｨｮ04ｨｰ. 5 08ｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ ｨｬｨ ｨｺｨ ﾂ0904ｨｮｨｦｨｬ070807ｨｦ07ｨｨ04ｨｺｨ ｨｪ ｨｮ000701ｨｰ ｨ - ｨｮｨｨ02ｨｪ0208ｨｰ 0208ｨｪｨ ｨｦ ｨ ｨｮ02ｨｪ07ｨｺ0701ｨｬｨ 09ｨｹ0504 (Sintrom 4 mg) ｨｮ ｨｮ07ｨｮ00ｨｹ 90% ｨｺｨ ｨｦ 09ｨ 0902ｨ 0908ｨｪ04 (Warfarin 5 mg) ｨｮ ｨｮ07ｨｮ00ｨｹ 10%, ｨｬ02 07 ﾂｨｴ0908ｨｰ ｨｮ01ｨｪ0101ｨ ｨｮｨｬｨｹ ｨ ｨｮ08ｨｦ0908ｨｪ04ｨｰ ｨｺｨ ｨｦ ｨｮ02 02ｨｦ01ｨｦｨｺ06ｨｰ ｨｦ080006ｨｮ02ｨｦｨｰ 0408ｨ 0908ｨｪ04 ｨｬｨｦｨｺ ｨｬ0709ｨｦｨ ｨｺ ｨｰ ｨｬ06ｨｮ04 ｨｮ01 ﾂｨｪｨｹ000400ｨ ｨ ｨｮ000409ｨｦｨ ｨｺ ﾂ0701 ｨｺｨ ｨｦ 0004ｨｰ 0905ｨｨｨｬｨｦｨｮ04ｨｰ 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｦ03ｨｹｨｬ02ｨｪ04 ｨｮ ｨｰ 0700ｨ ｨｪ ｨ - ｨｪ ｨｬ050102ｨｰ, ｨｬ02 01ｨｦｨ ｨｺ01ｨｬ05ｨｪｨｮ02ｨｦｨｰ ｨ 08ｨｹ 1ｨC ｨｬ050102ｨｰ (02ｨｦｨｺ. 2). 03 ｨｨ0209ｨ ｨｦｨｺｨｹｨｰ ｨｮ00ｨｹ ﾂ07ｨｰ 0208ｨｦ ﾂ05ｨｪ0700ｨ ｨｪ ｨｮ ｨC71% 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｮ08ｨｴｨｰ, 02ｨｪ ｨC12% 00ｨｴｨｪ ｨ - ｨｮｨｨ02ｨｪ06ｨｪ 0700ｨ ｨｪ ｨｺ0500ｨｴ ｨｦｨｨ01ｨｬ ｨｰ (ｨｺ08ｨｪ0101ｨｪ07ｨｰ ｨｨ09ｨｹｨｬ09ｨｴｨｮ04ｨｰ) ｨｺｨ ｨｦ ｨC22% 0700ｨ ｨｪ 0805ｨｪｨｴ ｨ 08ｨｹ 0007 ｨｨ0209ｨ ｨｦｨｺｨｹ ｨｰ (ｨｺ08ｨｪ0101ｨｪ07ｨｰ ｨ ｨｦｨｬ070909ｨ 0008ｨ ｨｰ) ｨｰ ｨｬ ｨｨ04ｨｺｨ ｨｪ 07ｨｦ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ ｨｬｨ ｨｰ ｨ ｨｪ ｨ ｨｪ 8 ｨｨ0907ｨｬ0906ｨｮ02ｨｦｨｰ (1,38%), ｨｺｨ ｨｦ 16 ｨ ｨｦｨｬ070909ｨ ｨｰ (2,78%). 09ｨｪｨ ｨｦｨｺ ｨｦｨｪｨ ｨｪ: ｨC 8 ｨｨ0907ｨｬ0906ｨｮ02ｨｦｨｰ ｨｬ02 INR ｨｬｨｦｨｺ09ｨｹ ｨｨ0209ｨ ｨｦｨｺ ｨｰ (1,38%), ｨC 14 ｨ ｨｦｨｬ070909ｨ ｨｰ ｨｬ02 INR ｨｬ0200ｨ ｨｨ0209ｨ ｨｦｨｺ ｨｰ (2,42%), ｨC 2 ｨ ｨｦｨｬ070909ｨ ｨｰ ｨｬ02 ｨｮ01ｨｪ0101ｨ ｨｮｨｬｨｹ ｨ ｨｮ08ｨｦ0908ｨｪ04ｨｰ (0,36%). 08ｨ 0807ｨｮ07ｨｮ0005 ｨｬｨ ｨｰ ｨ , ｨｮ0100ｨｺ09ｨｦｨｪｨｹｨｬ02ｨｪｨ ｨｬ02 00ｨ 01ｨｦ02ｨｨｨｪ ｨｬ06ｨｪｨ, ｨｺ0908ｨｪ07ｨｪ00ｨ ｨｦ ｨｦｨｺｨ ｨｪ070807ｨｦ0400ｨｦｨｺ05. 1,3, ｨ 0805ｨ 08ｨｮｨｦｨ 0004ｨｰ 08ｨ ｨｮｨ ｨｰ ｨ ｨｮ08ｨ ｨｰ ｨｬ ｨｨ04ｨｺ ｨｬ0802ｨｦ0908ｨ ｨｬｨ ｨｰ ｨ 08ｨｹ 0004ｨｪ 08ｨ 09ｨ ｨｺ ｨｨ04ｨｮ04 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｮ0007 ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｬ02 ｨｮ00ｨｹ ﾂ ｨｪ ｨ ｨｮｨｬｨ 00ｨｦｨｺｨｹ ｨｴｨｰ ｨｰ 0007 ｨｨ0209ｨ ｨｦｨｺｨｹ ｨｰ ｨｺｨ ｨｦ 00ｨｦｨｰ 0208ｨｦ080507ｨｺ06ｨｰ 0004ｨｰ ｨ 00ｨｴ0007ｨｰ. 03 ｨ 09ｨｦｨｨｨｬｨｹｨｰ 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｪ00ｨ ｨｦ ｨｮ02 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ ｨ 08ｨｪ02ｨｦ ｨ 0106ｨ ｨｪｨｹｨｬ02ｨｪ07ｨｰ ｨ - 08ｨｹ ｨｰ ｨｮ ｨｰ (ｨ ｨｮ ｨｺｨ %, 06ｨｪｨ ｨｪ00ｨｦ ). 05 ｨ ｨｮ04 ｨ ｨ ｨ ｨｦ ｨｮ0004ｨｪ ｨｹ0507 ｨｺｨ ｨｦ ｨｦｨｮｨｮｨｹ ｨ ｨｮ04 ｨｺｨ ｨｦ 01ｨｦ02ｨｨｨｪ06ｨｰ 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｦｨｺｨｹｨｪｨ ｨｮ04 ｨｮ01 ﾂｨｪｨｹ000400ｨ ｨ ｨｮ000409ｨｦｨ ｨｺ ﾂ0701 ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｮ ｨｬ050102ｨｰ.

4 ｨｪ00ｨ ｨｦ ｨｮ02 ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07 ｨ 00ｨｴ0007, ｨｮ0004ｨｪ ｨ 05ｨｬｨ ｨ ｨｮ04 ｨｺｨ ｨｦ ｨｮ0004 ﾂ0609ｨ ｨｬｨ ｨｰ 00ｨｴｨｪ ｨｺｨ 0901ｨｦ07 ﾂ02ｨｦ ｨｦｨｺ06ｨｪ ｨｬ0905ｨｮ02ｨｴｨｪ, ｨｮ0004ｨｪ ｨ ｨｮ ｨｮ01ｨｹｨｺｨｦｨｬ ｨｦ0908ｨｴｨｮ04ｨｰ ｨｮ01ｨｬ ｨｦ ｨｮ0004ｨｪ ｨ ｨｪ ｨ ｨｨｨｬｨｦ06ｨｪ, ｨｮ0004ｨｪ ｨｺｨ ｨｺｨ ｨｦ ｨｮ ｨｦ ｨｪ04ｨｮ04 00ｨｴｨｪ ｨｨ0907ｨｬ090702ｨｬ090705ｨｦｨｺ06ｨｪ ｨｦｨｮ070108ｨｴｨｪ ( ﾂ07ｨｰ ｨｨ0907ｨｬ090702ｨｦ0508ｨ ｨｰ) ｨｺｨ ｨｦ ｨｮ0004ｨｪ ｨ 08ｨｹ ｨｰ ｨ ｨｮｨｨ02ｨｪ0208ｨｰ 01ｨｦ050107ｨｮ ｨｰ 0508ｨ ｨｰ ｨ ｨｪｨｴｨｬ06ｨｪ0701 ｨｦｨ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｪ04ｨｬ0609ｨｴｨｮ04 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨ ｨｪ ｨ - ｨｺ090700ｨｴｨｪｨｦｨ ｨｨ ｨｰ 0208ｨｦ0001 ﾂ08ｨ ｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ, ｨｦ 0102 ｨｪｨ 0008ｨｪ0200ｨ ｨｦ ｨｺｨ ｨｪ 06ｨｪｨ ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｺｨ ｨｦ ｨｪｨ 0208ｨｪｨ ｨｦ ｨｮ01ｨｪ02 ﾂ07ｨｰ 00ｨｦｨ ｨｪｨ 0208ｨｪｨ ｨｦ ｨ ｨｮｨｬｨ 00ｨｦｨｺ ｨｮ ﾂ06ｨｮ ｨｦｨ ｨｺｨ ｨｦ ｨ ｨｮｨｨ02ｨｪ0705ｨｰ 08ｨ ｨｦ ｨｮ04ｨｬｨ ｨｪ00ｨｦｨｺｨｹ 09ｨｹ0507 ｨｮ0007 ｨｪｨ 0802ｨｦｨｮ ｨｰ 00ｨｦｨ 0004ｨｪ 0202ｨ 09ｨｬ ｨｴｨｪ 01ｨｦｨ ｨｦ000400ｨｦｨｺ06ｨｪ, 02ｨ 09ｨｬｨ ｨｺ020100ｨｦｨｺ06ｨｪ ｨｺｨ ｨｦ 0507ｨｦ0806ｨｪ ｨｦ06ｨｪ, ｨｬ02 ｨｮｨｺ0708ｨｹ 0004 ｨｬ0208ｨｴｨｮ04 00ｨｴｨｪ ｨｨ0907ｨｬ0906ｨｮ02ｨｴｨｪ ｨｺｨ ｨｦ 00ｨｴｨｪ ｨ ｨｦｨｬ070909ｨ 00ｨｦ06ｨｪ. 05 ｨｮ01 ﾂｨｪｨｹ000400ｨ ｨ ｨｮ000409ｨｦｨ ｨｺ ﾂ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 0700ｨ ｨｪ ｨｮ08ｨｴｨｰ 00ｨｦｨ % 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨ ｨｪ ｨｬ050102ｨｰ, 00ｨｦｨ % ｨ ｨｪ ｨｬ050102ｨｰ, 00ｨｦｨ % ｨ ｨｪ ｨｬ050102ｨｰ, 00ｨｦｨ % ｨ ｨｪ ｨｬ050102ｨｰ ｨｺｨ ｨｦ 00ｨｦｨ % ｨ ｨｪ ｨｬ0501ｨ ｨｨ0209ｨ ｨｦｨｺｨｹ ｨｰ 0004ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｮ08ｨｴｨｰ, 0700ｨ ｨｪ 02ｨｪ00ｨｹｨｰ ｨｨ0209ｨ ｨｦｨｺ ｨｰ ｨｮ ｨC71% 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ, 06ｨｪｨ ｨｪ00ｨｦ ｨC70% 00ｨｴｨｪ ｨｴｨｪ ｨｬ ｨｪ. 4, ｨｦ02ｨｨｨｪ07ｨｰ 0809ｨ ｨｺ00ｨｦｨｺ07 ｨ ｨｪｨ ｨｦ ｨｹ00ｨｦ ｨｦ0001- ﾂ08ｨ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ 0208ｨｪｨ ｨｦ ｨ ｨｮ02ｨ 0507ｨｰ ｨｺｨ ｨｦ ｨ ｨｮｨｬｨ 00ｨｦｨｺ07 ｨ ｨｪ 07 ｨ ｨｮｨｨ02ｨｪ07ｨｰ ｨｮｨｺ0200ｨ ｨｦ 02ｨｪ00ｨｹｨｰ 00ｨｴｨｪ ｨｺｨ ｨｨ0709ｨｦｨｮｨｬ06ｨｪｨｴｨｪ 00ｨｦ' ｨ 0100ｨｹｨｪ ｨｨ0209ｨ ｨｦｨｺ06ｨｪ ｨｴｨｪ, 00ｨｦｨ ｨｦｨｮｨｮｨｹ ｨ 08ｨｹ % ﾂ09ｨｹｨｪ0701 ｨｨ0209ｨ ｨ ｨｰ ｨｹ ｨC12% 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｮ08ｨｴｨｰ ｨｨ04ｨｺｨ ｨｪ ｨｺ0500ｨｴ ｨｨ0209ｨ ｨｦｨｺ ｨｰ, 01ｨｦｨ 08ｨｦｨｮ0006ｨｨ04ｨｺｨ ｨｪ 8 ｨｨ0907ｨｬ0906ｨｮ02ｨｦｨｰ (09ｨ 09ｨｦ06ｨｰｨｬ060009ｨｦ02ｨｰ-0708ｨｦ02ｨｰ), 0807ｨｮ07ｨｮ00ｨｹ 1,38%, 06ｨｪｨ ｨｪ00ｨｦ 2,2ｨC4,8% ｨｴｨｪ ｨｬ ｨｪ. 1,3,4 0908ｨｹ ｨC22% 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｨ04ｨｺｨ ｨｪ ｨｺｨ ｨｪ ｨｮｨｦｨ 08ｨ 09ｨ ｨｺ ｨｨ04ｨｮ ｨｪｨｴ ｨ 08ｨｹ 0007 ｨｨ0209ｨ ｨｦｨｺｨｹ ｨｰ INR, 01ｨｦｨ 08ｨｦｨｮ0006ｨｨ04ｨｺｨ ｨｪ 16 ｨ ｨｦｨｬ070909ｨ ｨｰ (09ｨ 09ｨｦ06ｨｰ-ｨｬ060009ｨｦ02ｨｰ-0708ｨｦ02ｨｰ), 0807ｨｮ07ｨｮ00ｨｹ 2,78% 06ｨｪｨ ｨｪ00ｨｦ 3,2ｨC7,8% ｨｴｨｪ ｨｬ ｨｪ. 1,3, ｨ ｨ ｨｬ06ｨｪｨｴｨｪ ｨ ｨｦｨｬ070909ｨ 00ｨｦ06ｨｪ 05ｨｹ00ｨｴ ｨ ｨｮ04ｨｰ ｨｨ0209ｨ ｨｦｨｺ ｨｰ INR, 0700ｨ ｨｪ ｨ ｨｮｨｬｨ 0004ｨｰ 00ｨ 0100ｨｹ ﾂ0907ｨｪ04ｨｰ ｨｰ ｨ ｨｮ08ｨｦ0908ｨｪ04ｨｰ ｨｴｨｪ 02ｨ 09ｨｬ05ｨｺｨｴｨｪ, 0004ｨｰ ｨｬ04 ｨｮ01ｨｬｨｬｨｹ0902ｨｴｨｮ04ｨｰ 00ｨｴｨｪ ｨ ｨｮｨｨ02ｨｪ06ｨｪ ｨｬ02 00ｨｦｨｰ ｨｨ0209ｨ ｨｦｨｺ06ｨｰ ｨｰ ｨｺｨ ｨｦ 0004ｨｰ ｨｬ ｨｰ 0405ｨｦｨｺ08ｨ ｨｰ 00ｨｴｨｪ ｨ - ｨｮｨｨ02ｨｪ06ｨｪ. 0701ｨｬ080209ｨ ｨｮｨｬｨ 00ｨｦｨｺ05, 0208ｨｪｨ ｨｦ ｨ ｨｪｨ 00ｨｺｨ ｨ ｨｮ000409ｨｦｨ ｨｺｨｹｨｰ ﾂ07ｨｰ ｨｺｨ ｨｦ ｨｨｨｬｨｦｨｮ ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ 00ｨｴ0007ｨｰ ｨｪｨ 0008ｨｪ07ｨｪ00ｨ ｨｦ ｨｮ ｨ ｨｪｨｴｨｬ06ｨｪｨ ｨｦｨ ｨ, ｨｦ ｨｪｨ 0104ｨｬｨｦ ｨｨ0705ｨｪ ﾂｨｴ090700ｨ 06ｨｦｨｺ05 ｨｮ02 ｨｹ ﾂ0609ｨ, 00ｨｦｨ ｨｪｨ 0208ｨｦ ﾂｨｨ ｨｨ0209ｨ ｨｦｨｺｨｹｨｰ ｨｮｨｺ0708ｨｹｨｰ 0004ｨｰ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ07ｨｰ ｨ - 00ｨｴ0007ｨｰ, ｨｪｨ ｨｦ 04 ﾂ ｨｮ ｨ ｨｪ00ｨｦ0804ｨｺ00ｨｦｨｺ ｨ 09ｨｬ05ｨｺ0701 ｨｮ ｨｦｨ 01ｨｹｨｮ04 ｨｺｨ ｨｦ 00ｨｦｨ 00ｨｹｨｮ07 01ｨｦ05ｨｮ0004ｨｬｨ ｨｪｨ ｨｬ04ｨｪ ｨｺｨ ｨ 0902ｨｪ ｨｦ02ｨｰ, 08ｨ 0905 ｨｬｨｹｨｪ ｨｨ0209ｨ ｨｦｨｺ ｨｮ04. ABSTRACT Experience of monitoring patients in the anticoagulant therapy 08. MARAGKOS, 00. BELLIA, 03. DIGENOPOULOU, V.TSEVRENIS, G. THEODOSIADIS, N. VGONTZA, A. GA1 7OU, E. NOMIKOU, A. LAGIANDREOU, I. GEORGOPOULOS, A. KOUSOULAKOU, E. KONTOPOULOU-GRIVA 1st Blood Transfusion Center, Hippokration General Hospital of Athens, Greece 09rchives of Hellenic Medicine 2000, 17(Supplement A):110ｨC114 OBJECTIVE It is generally assumed that oral anticoagulant therapy requires frequent laboratory controls to assure therapeutic efficacy and to prevent life threatening adverse events. We performed this study in order to evaluate the therapeutic efficacy and the adverse events of our Anticoagulant Therapy Outpatient Clinic. METHOD Our outpatient clinic began its activity in 1984 when we were treating 30 patients and we are now monitoring 850 of them. In 1998 we treated 578 outpatients with anticoagulant therapy. 1 7rom those 371 patients had mechanical heart valves, 93 atrial fibrillation, 24 mitral or aortic valvular disease, 59 thrombosis, 11 congenital thrombophilia, 15 acquired thrombophilia and 5 pregnancy in high risk. Their follow up constituted of the history of their disease, laboratory testing with different thromboplastins (ISI: 1.0ｨC1.03) and monitoring of the anticoagulant therapy. A special card of attendance was given to each one, as well as a book with instructions and precautions with a special report to food and drug interactions as well as to precautions during surgical and dental interventions or pregnancy. The therapeutic target INR for the patients with mechanical heart valves was 2.5ｨC3.5, for those with arteriovenous bypass, atrial fibrillation, myocardial infraction, pulmonary embolism, and deep vein thrombosis (DVT) was 2ｨC3 and for prevention of DVT 2ｨC2.5. The prescribed anticoagulants were acenocoumarol or warfarin with or without aspirin and low molecular weight heparins in specific situations. RESULTS The mean frequency of laboratory testing and monitoring of

5 ｨｺｨ ｨｦ ｨｮ01ｨｪ patients was three weeks with range 1ｨC5 of weeks. The target INR was achieved in approximately 68ｨC71% of our patients. In 1998 eight thrombotic events occured at INR lower than the therapeutic one, 14 bleeding events at INR higher and two severe bleeding episodes because of oral anticoagulants plus aspirin administration. Our results are in agreement with large clinical trials in the current literature. CONCLUSIONS The efficacy of anticoagulant therapy necessitates a close control of the actual intensity of anticoagulation that requires both patient ｯs obedience and close monitoring by a specifically educated doctor in order to prevent life threatening adverse events. All of these are achieved in specialized anticoagulant therapy outpatient clinics, that must be organized at certain hospitals all over the country. Key words: Adverse events, Anticoagulant therapy, Outpatient clinic Bｨｦ0905ｨｦ070009ｨ 0208ｨ 1. COCCHERI S, COSMI B, PALARETI G. Oral anticoagulants: Efficacy and safety. The Italian experience. State of the art. Semin Thomb Haemost 2000, 26:43ｨC46 2. TABOSKI U, MULLER-BERGAHANS G. State of the art patient self management for control of oral anticoagulation. Semin Thromb Haemost 1999, 25:43ｨC47 3. POLLER L, SHIACH CR. MACCALLUM PK, JOHANSEN AM, MUSTER AM, MAGALHA ES ET AL. Multicentre randomized study of computerized anticoagulant dosage. European Concerted Action on anticoagulation. Lancet 1998, 352:1505ｨC CHIQETTE E, AMATO MG, BUSSEY HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes and health care costs. Arch Intern Med 1998, 158:1641ｨC HIRSH J, LEVINE M. Confusion over the therapeutic range for monitoring oral anticoagulant therapy in North America. Thromb Haemost 1988, 59:129ｨC COSSELINI R, OWINGS JI, WHITE RH, HUTCHINSON P, BRANCH J, MAHA- CKIAN K ET AL. Comparison of point of care instruments. Designer for monitoring oral anticoagulation with standard laboratory methods. Tromb Haemost 2000, 83:698ｨC WARRKE HH, 1 7ORBERG E, SVOLBA G, JIMENEZ-BOJ E, KRINNINGER B. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000, 83:661ｨC665 Corresponding author: K. Maragkos, 44 Tinou street, Aghia Paraskevi GR Athens, Greece